Balance Sheet Components

6 Months Ended

Jun. 30, 2021

Balance Sheet Related Disclosures [Abstract]

Note 3—Balance Sheet Components

Prepaid expenses and other current assets consisted of the following (in thousands):


	June 30, 2021		December 31, 2020
Prepaid research and development	$	6,716	$	2,462
Prepaid bonus		1,192		409
Prepaid insurance		826		2,480
Prepaid clinical trial		184		944
Other		1,014		331
Total prepaid expenses and other current assets	$	9,932	$	6,626

Property, plant and equipment, net consisted of the following (in thousands):


	June 30, 2021			December 31, 2020
Leasehold improvements		1,863			—
Furniture and fixtures		676			—
Computer equipment		529			95
Laboratory equipment		460			—
Construction in progress		30,465			201
		33,993			296
Accumulated depreciation		(126	)		(9	)
Property, plant and equipment, net	$	33,867		$	287

Included in construction in progress at June 30, 2021 was $30.3 million of costs associated with the Build-to-Suit lease (see Note 10).

Depreciation expense was $85,000 and $117,000 for the three and six months ended June 30, 2021, respectively. There was no depreciation expense for the three and six months ended June 30, 2020.

Accrued expenses and other current liabilities consisted of the following (in thousands):


	June 30, 2021		December 31, 2020
Accrued research and development	$	14,508	$	2,106
Accrued compensation		3,210		1,766
Accrued professional and consulting fees		1,372		999
Accrued property, plant, and equipment		1,309		173
Accrued clinical trial		959		—
Other		678		91
Total accrued expenses and other current liabilities	$	22,036	$	5,135